NCT06346392 2026-03-09
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
Clinical Trials
7 trialsNCT03686488 2026-03-02
TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT07212933 2025-10-08
RAK in GC
Chinese PLA General Hospital
Phase 2 Recruiting
NCT03368963 2025-01-07
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Emory University
Phase 1/2 Active not recruiting
NCT04999761 2024-09-25
AB122 Platform Study
Taiho Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT02500043 2024-09-03
Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer
Taiho Oncology, Inc.
Phase 3 Completed
NCT05029102 2024-02-12
TAS-102 and Anlotinib in ≥3 Lines mGC
Zhejiang University
Phase 2 Unknown